Hold onto your antioxidants—this episode of the podcast is a full-court press on free radicals!

When it comes to the science of antioxidants and topical formulations, we have the right person-dermatologist Dr. Mark Lupin debuts as a faculty expert on the podcast to practically decipher what you NEED to know

Also debuting on the podcast, but as a guest co-host, is dermatologist Dr. Vincent Richer who's ready to fire up the hot seat with pharmacist Aaron Sihota to ask the tough questions.

Don’t miss our RAPID FIRE round where we break down must-know ingredients faster than you can say ‘free radical!’ 🚀🦸

We dust off your old sunscreen routine and show you why slathering on antioxidants might just be your skin’s new secret weapon. Tune in for a fast-paced conversation that hops effortlessly from clinic chairs to concert halls, apples to ferulic acid, and vitamin C to conjugated retinol. Here, myths get busted, fancy science terms get decoded, and you’ll finally learn the ABCs of a top-tier skincare regimen—no sunscreen-shy patients or lost winter gloves required. ☀️🧴🍏

Trust us, this episode is your on-demand playbook reference for practice! 🎧📖

Learning Objectives:

1. Antioxidant Fundamentals: Understand how environmental aggressors cause oxidative stress on the skin and how antioxidants serve as powerful defenders. The latest science on how these mighty molecules supercharge your broad-spectrum sunscreen and reduce UV-induced damage?🌞🔬 ‍🍃
2. Key Ingredients in formulations: Identify evidence-based antioxidant ingredients, learn why they’re paired together, and explore optimal formulation concentrations and pH levels for maximum skin benefits. 🍏🔬
3. Critical Evaluation of Research: Gain tools and strategies to discern credible studies from marketing fluff, ensuring more informed clinical recommendations. 📚🔎
4. Integration into Practice: Discover practical tips for incorporating antioxidants into morning routines, combining them effectively with sunscreens, and managing patient expectations. ⏰✔️
5. Future Directions in Dermatology: Explore the promising frontier of antioxidant research, including their potential to complement medical interventions and the call for standardized validation measures. 🔭🚀

Get ready for an antioxidant masterclass 🤓✨— that’ll have you completely rethinking your recommendations!

ABOUT DR.MARK LUPIN MD FRCPC DABD

VICTORIA, BC

Dr. Lupin is a Board-certified Dermatologist, Founder in 1998 of Cosmedica Laser Centre in Victoria, British Columbia and Chief Clinical Officer of MedSpa Partners Inc.He has degrees in Mathematics, Music and Medicine having studied at the University of Toronto, University of British Columbia, Dalhousie University, Indiana University and the University of Southern California. He has special interests in photodermatology and laser medicine, having studied under Professor John Hawk at St John’s Institute of Dermatology, London, England. He is active with research and education, has additional subspecialty training in Neurology and is past President of the Canadian Laser Aesthetic Surgery Society.

As a concert violinist, Dr Lupin has performed as soloist at Carnegie Hall, New York and with major orchestras around the world. He is Concertmaster of the World Doctors Orchestra (WDO), performing most recently in Australia at the Sydney Opera House, with all proceeds donated to charities. His research interests extend to space medicine and fluid dynamics where he has been active with mathematical modeling for space tools and has developed several patent pending energy efficient devices.

ABOUT Dr. Vincent Richer MD FRCPC

VANCOUVER, BC

Dr Vincent Richer practices cosmetic dermatology at Pacific Derm Atelier in Vancouver and holds a position as Clinical Assistant Professor at the University of British Columbia’s Department of Dermatology and Skin Science. He trained at Université de Montréal in Medicine and Dermatology and completed a fellowship in Photobiology and Cutaneous Laser Surgery at UBC. He is involved as a subinvestigator in cosmetic clinical trials, has published 35+ peer reviewed scientific articles and is active in undergraduate, graduate and continuing medical education.

EPISODE SUPPORTED BY SKINCEUTICALS AND SKINBETTER SCIENCE.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Unlocking the Secrets of Clear Skin (and Soggy Shoes) in Amsterdam! 🌧️👟✨

Ready to revolutionize your approach to atopic dermatitis? 🤔

Join us on the latest episode of the Skin and Joints podcast, live from the EADV in Amsterdam! 🇳🇱

Dr. Marissa Joseph and Dr. Max Sauder, braved the Dutch downpours to bring you exclusive insights into lebrikizumab—the new kid on the block that's making waves 🌊 in eczema treatment.

Discover how this IL-13 inhibitor is changing the game 🎯 with its long-term efficacy, flexible dosing schedules, and impressive safety profile. 📊 We'll dive deep into the ADJOIN study's three-year data, discuss where lebrikizumab fits into the current treatment landscape for their respective practices 🩺, and explore how it could be a game-changer for your patients..

🗺️Get a taste of our guests' Amsterdam adventures—from waterlogged wanderings 🚶‍♀️🌧️ to culinary delights 🍽️ Plus, find out why Max might be shopping for a princess dress 👗 before the next conference 🏰🎢

🎙️ Tune in and get ready to see atopic dermatitis treatment in a whole new light! 💡

Learning Objectives:

1. Understand the mechanism of action of lebrikizumab in treating atopic dermatitis, focusing on its role as an IL-13 inhibitor 🧬.
2. Analyze the long-term efficacy and safety data from the ADjoin study, emphasizing the durability of lebrikizumab over a three-year period 📈.
3. Compare the dosing regimens (biweekly vs. monthly) of lebrikizumab and their implications for patient adherence and treatment outcomes 📆.
4. Evaluate how lebrikizumab fits into current clinical practice for atopic dermatitis, considering patient preferences and the spectrum of available therapies 🩺.
5. Recognize the importance of expanding therapeutic options in atopic dermatitis management and how to personalized patient care 🎯.

ABOUT DR.MARISSA JOSEPH

Dermatologist, Toronto, ON

Marissa Joseph, MSc, MD, FRCPC ( Pediatrics), FRCPC ( Dermatology)

Dr. Marissa Joseph is a board certified Pediatrician and Dermatologist after completing Pediatric training at the Hospital For Sick Children, following with a Dermatology residency at the University of Toronto. She completed a MSc in Community Health at the Dalla Lana School of Public Health.

Dr. Joseph is full time academic faculty at the Unee Schachter Dermatology Centre at Women's College Hospital. She also works at the Hospital For Sick Children where she manages children with complex dermatologic disease in outpatient and inpatient settings, as well as a pediatric laser treatment program. Dr. Joseph enjoys her diverse practice in general adult, pediatric and surgical dermatology. Her clinical and research interests include inflammatory skin disorders such as psoriasis, atopic dermatitis, and hidradenitis suppurativersity of Toronto. She has received and has been nominated for teaching awards in both undergraduate and postgraduate medical education. Dr. Joseph is the Medical Director of the Ricky Kaniva; genodermatoses, and equity, diversity and inclusivity.

Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School.

Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic.

Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions.

Epsode supported by an Independent Medical Educational Grant from Lilly.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

🚴‍♀️ Biking and the Battle Against Itch! 🎙️

Live from the charming canals of Amsterdam at the EADV 2024 meeting, we sit down with the ever-energetic Dr. Perla Lansang from Toronto!

🍁 She's ditched cabs and metros to embrace the Dutch biking culture, even bringing her own bike across the pond! 🚲🌍 From navigating streets with more bikes than people 😲 to packing rain ponchos for unpredictable weather ☔, Dr. Lansang shares her love for the city.

🍽️ She's on a mission to find the best delectable mini Dutch pancakes topped with butter and powdered sugar 🥞✨. And while we couldn't coax the secret behind her infamous kale smoothie 🥬🥤, we dive into something even more exciting.

We explore late breaking fresh new data presented at EADV on nemolizumab, the new therapeutic targeting IL-31 that's set to revolutionize atopic dermatitis treatment! What does this new 56-week data from an interim analysis of the phase III ARCADIA long-term extension study mean for your patients?

🧪🔥 Discover how this game-changing drug offers rapid itch relief—some patients feel better in just days! 😮🧖‍♂️

We'll unpack nemolizumab’s long-term efficacy and safety in atopic dermatitis, discuss the stellar safety profile, and delve into how it is poised to transform patient care by improving sleep 😴 and overall quality of life 🌟.

This episode is packed with laughs 😂, insightful clinical pearls 🩺, and a sprinkle of Dutch delight! 🎧🌷

Learning Objectives:

1. Understand the pivotal role of IL-31 in atopic dermatitis and why nemolizumab's targeting of this cytokine is a breakthrough.
2. Review the design, key findings, and clinical significance of the Arcadia 1 and 2 long-term extension data up to 56 weeks.
3. Discuss the rapid efficacy and excellent safety profile of nemolizumab and its impact on itch relief, clearance and patient adherence.
4. Evaluate the clinical implications of integrating nemolizumab into practice and its potential to transform atopic dermatitis management.

ABOUT Dr. Perla Lansang, MD, FRCPC ( Dermatology)

Toronto, ON

Dr. Perla Lansang is a full-time staff dermatologist and associate professor in the Division of Dermatology, University of Toronto where she is the Division Head of Dermatology at Sunnybrook Health Sciences Centre. She is also cross appointed at the Section of Paediatric Dermatology at the Hospital for Sick Children, and the Division of Obstetric Medicine at Sunnybrook Health Sciences Centre.

She completed her medical school and dermatology residency at the University of the Philippines-Philippine General Hospital. Having done fellowships in paediatric dermatology at The Hospital for Sick Children and in advanced medical dermatology at Sunnybrook Health Sciences Centre, Dr. Lansang’s practice is a mixture of pediatric, adolescent, and adult dermatology, with a special focus on psoriasis, atopic dermatitis, cutaneous lymphoma, pregnancy dermatoses, and general medical dermatology. She has a special interest in immune-mediated skin diseases and has extensive clinical and research experience in many areas of immunodermatology.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca